Page last updated: 2024-12-06

phenyl beta-d-glucopyranoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenylglucoside: RN given refers to (beta-(D))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65080
CHEMBL ID4105357
CHEBI ID8083
SCHEMBL ID1004929
MeSH IDM0484467

Synonyms (49)

Synonym
bdbm36025
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxy-tetrahydropyran-3,4,5-triol
.beta.-d-glucopyranoside, phenyl
beta-d-glucopyranoside, phenyl
phenyl beta-d-glucoside
einecs 215-978-6
phenol glucoside
glucopyranoside, phenyl-, beta-d-
brn 0087517
1464-44-4
aryl beta-d-glucoside
C03097
phenylglucoside
phenyl beta-d-glucopyranoside
phenyl beta-d-glucopyranoside, 97%
phenyl-beta-d-glucopyranoside
phenyl-beta-d-glucoside
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxyoxane-3,4,5-triol
BMSE000770
HMS1614E16
P0178
mfcd00204281
AKOS001669140
4w3pgi3766 ,
unii-4w3pgi3766
5-17-07-00046 (beilstein handbook reference)
phenyl .beta.-d-glucoside
glucopyranoside, phenyl-, .beta.-d-
phenyl .beta.-d-glucopyranoside
SCHEMBL1004929
CHEBI:8083
c12h16o6
phenyl-.beta.-d-glucopyranoside
phenyl-.beta.-d-glucoside
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxytetrahydro-2h-pyran-3,4,5-triol
CCG-249827
AS-59078
NCGC00385978-01
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-phenoxy-tetrahydro-2h-pyran-3,4,5-triol
Q27107738
CHEMBL4105357
D82047
DTXSID40883677
A884507
phenyl beta -d-glucopyranoside
CS-W012565
gtpl12455
HY-W011849
phenyl-(c)micro-d-glucopyranoside

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"The metabolic fates of 14C-phenol and its model plant conjugates 14C-phenyl glucoside and 14C-phenyl 6-O-malonyl-glucoside have been compared following equimolar oral dosing to rats (1."( A comparison of the metabolic fate of phenol, phenyl glucoside and phenyl 6-O-malonyl-glucoside in the rat.
Edwards, VT; Hutson, DH; Jones, BC, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
glycogen degradation I850

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 16Homo sapiens (human)EC50 (µMol)482.09200.00490.15500.2500AID1618141; AID1619328; AID1619330; AID1619458; AID1619466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityTaste receptor type 2 member 16Homo sapiens (human)
protein bindingTaste receptor type 2 member 16Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
endoplasmic reticulumTaste receptor type 2 member 16Homo sapiens (human)
trans-Golgi networkTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
external side of plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1439304Inhibition of Ascaris suum T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dye b2017European journal of medicinal chemistry, Mar-10, Volume: 128Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases.
AID1439303Inhibition of Brugia malayi T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dye 2017European journal of medicinal chemistry, Mar-10, Volume: 128Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases.
AID1439305Inhibition of Mycobacterium tuberculosis T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioM2017European journal of medicinal chemistry, Mar-10, Volume: 128Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases.
AID1439306Inhibition of Shigella boydii T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol green dy2017European journal of medicinal chemistry, Mar-10, Volume: 128Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases.
AID1439307Inhibition of Salmonella typhimurium T6PP using T6P as substrate assessed as fraction of enzyme unbound with compound by measuring ratio of initial velocities of T6P substrate hydrolysis in presence and absence of compound at 1 mM after 5 mins by BioMol g2017European journal of medicinal chemistry, Mar-10, Volume: 128Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's2 (12.50)18.2507
2000's4 (25.00)29.6817
2010's6 (37.50)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.61 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]